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For patients on peritoneal dialysis (PD), the development of
peritonitis, the decline of residual kidney function, and the
loss of peritoneal membrane function are central events that
affect both patient and technique survival. The use of glucose
as the osmotic agent in conventional PD solutions may
increase the susceptibility to each of these events. However,
its use may also be associated with systemic metabolic
perturbations and, in turn, an increase in cardiovascular
morbidity. Both in vitro and in vivo evidence suggest that
both the local peritoneal and systemic toxicity induced by the
use of glucose may be in part mediated by the presence of
glucose degradation products (GDPs) coupled with the
hyperosmolarity, reduced pH, and use of lactate as the buffer
in conventional PD solutions. Therefore, the use of neutral
pH, low-GDP (NpHLGDP), bicarbonate-buffered PD solutions
may represent a promising strategy to attenuate some of
these adverse effects. However, the impact of these novel
solutions on clinical outcomes remains largely unknown. In
this review, we will highlight evidence regarding the
biocompatibility of NpHLGDP PD solutions, review the utility
of current biomarkers in the evaluation of biocompatibility,
and discuss the clinical outcome data
with these solutions.
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Central to the success of peritoneal dialysis (PD) is the long-
term preservation of the peritoneal membrane. In contrast to
hemodialysis (HD) in which the specifications of the dialyzer
are known and can be altered, the peritoneal membrane is a
biological membrane and susceptible to injury. Peritoneal
membrane changes seen with increasing duration on PD
include fibrosis, and both quantitative and qualitative
changes within the peritoneal microcirculation.1 These
changes correlate with increasing small-solute permeability
and a reduction in peritoneal ultrafiltration (UF) capacity,2,3
and may be partially responsible for the shortened technique
survival of PD relative to HD.4,5
The observation that these deleterious changes occurred
under conditions of chronic exposure to conventional
hyperosmolar glucose-containing, lactate-buffered, low-pH
PD solutions has led to the conclusion that the composition
of conventional PD solutions is responsible. If dialysate
incompatibility contributes to technique failure, then manip-
ulation of conventional PD solution composition represents a
therapeutic target to improve patient outcomes on PD.
Possible strategies include the use of non-glucose-based
PD solutions, or, alternatively, modification of other
dialysate components to minimize the local peritoneal and
systemic toxicity imposed by glucose. The latter strategy
involves the use of glucose-based, neutral pH, low glucose
degradation product (NpHLGDP) PD solutions to minimize
the toxicity mediated by GDPs and low pH. Both ex vivo
and animal data provide convincing evidence that peritoneal
and systemic exposure to GDP and low pH have been
linked to peritoneal membrane injury, impairment of
local peritoneal host defenses, renal injury, and systemic
inflammation.
We will summarize the current knowledge regarding the
bioincompatibility of conventional PD solutions, while
highlighting the variability in the composition of commer-
cially available, NpHLGDP PD solutions. The impact of these
solutions on clinical outcomes, including peritoneal mem-
brane function, preservation of residual kidney function
rev iew http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 31 July 2010; revised 3 October 2010; accepted 20 October
2010; published online 19 January 2011
Correspondence: Joanne M. Bargman, Division of Nephrology, Department
of Medicine, University Health Network, 8NU-840, 200 Elizabeth Street, Toronto,
Ontario, Canada M5G 2C4. E-mail: joanne.bargman@uhn.on.ca
814 Kidney International (2011) 79, 814–824
(RKF), PD-related infectious complications, as well as patient
and technique survival will be presented.
PRODUCTION OF LOW-GDP, NEUTRAL pH SOLUTIONS
Heat (autoclave) sterilization of conventional glucose-based
PD solutions has given rise to elevated levels of dialysate
GDPs that are produced during both manufacturing and
storage.6,7 To reduce this caramelization of glucose, it is
buffered with lactate and the solution is maintained at a low
pH (5.0–6.0).6 In contrast, NpHLGDP PD solutions have a
final pH of approximately 6.2–7.4. The use of a multi-bag
system allows for separation into two compartments: a low-
pH glucose compartment, which minimizes the production
of GDPs during heat sterilization and storage,8,9 and a buffer
compartment, which can be lactate, a bicarbonate/lactate
mixture, or bicarbonate alone (Table 1). This also separates
calcium from bicarbonate, avoiding precipitation of the two
until both compartments are mixed immediately before
instillation. The final GDP content and type varies by
solution and manufacturer10 (Figure 1).
LOCAL ‘BIOINCOMPATIBILITY’ OF CONVENTIONAL PD
SOLUTIONS
Glucose
Uremia initiates structural peritoneal membrane changes that
are exacerbated with increasing duration on PD.1 Peritoneal
biopsy registry data suggest that these changes are seen
across all resident cells of the peritoneum.1 These changes
include the loss of the mesothelial monolayer, thickening of
the submesothelial compact collagenous zone, neovascular-
ization, and additional vascular changes including subendo-
thelial hyalinization of post-capillary venules, with accom-
panying obliteration or narrowing of the vascular lumen.1
Ultrastructurally, ‘diabetiform’ vascular changes are observed,
including lamellation of the capillary and mesothelial
basement membrane.11–14 These changes raise the possibility
that the presence of glucose in conventional PD solutions
may be mediating these deleterious effects. Similar changes
have been reproduced in animal models exposed
to hypertonic, glucose-based dialysate.15
Moreover, glucose also has a dose-dependent inhibitory
effect on mesothelial cell proliferation in human and animal
models.16–19 This toxicity may be mediated by oxidative
stress.18 Mitochondrial DNA damage has been demonstrated
on exposure of human peritoneal mesothelial cells (HPMCs)
to glucose.20 Compared with other hyperosmolar solutes
such as mannitol and glycerol, the inhibitory effects of
glucose on mesothelial cells seems to be greater, implying
both an effect of hyperosmolality and an intrinsic toxic effect
of glucose on mesothelial cell proliferation.21 Evidence that
these glucose-induced structural changes translate into
adverse effects on membrane function stems from a single-
center observational cohort study by Davies et al.22 In this
study, patients with greater early and cumulative exposure
to higher glucose concentrations experienced more rapid
increases in small-solute permeability and faster deterioration
of membrane function. However, the possibility that the need
for higher dialysate glucose exposure may have been in
response to declining RKF or to inadequate peritoneal UF, in
the face of worsening peritoneal membrane function, cannot
be excluded.
Glucose degradation products
In 1986, the observation by Henderson et al.23 that PD
infusion pain correlated with the shelf life of the PD solution
being infused ultimately gave rise to the discovery of GDPs in
conventional PD solutions. The shelf life of the conventional
dialysis solutions was found to correlate with increasing
GDP content, as detected by photospectrometric analysis.23
Since that time, increasing evidence from in vitro and animal
studies suggests that the local toxicity of glucose may be,
in part, related to the presence of GDPs in conventional PD
solutions.
Table 1 | Commercially available, neutral pH, low-GDP
peritoneal dialysis solutions and conventional peritoneal
dialysis solution
Buffer (mmol/l)
Chambers Lactate Bicarbonate Final pH
Balance 2 35 — 6.8
Bicavera 2 — 34/39 7.1
Gambrosol Trio 3a 39–41 — 6.5
Physioneal 2 10/15 25 7.3
Conventional 1 35/40 — 5.0–5.4
Abbreviation: GDP, glucose degradation product.
aChambers to allow for final glucose concentration of three different concentrations.
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Figure 1 | The GDP content among commercially available
neutral pH, low-GDP peritoneal dialysis solutions (solutions
1–4) compared with the GDP content of conventional
peritoneal dialysis solutions (solution 5). Adapted from
Erixon M. et al.10 3-DG, 3-deoxyglucosone; 3,4-DGE, 3,4-
dideoxyglucosone-3-ene; 5-HMF, 5-hydroxymethyl furaldehyde;
AcA, acetaldehyde; FoA, formaldehyde; GDP, glucose degradation
product. *GDP concentrations for conventional peritoneal dialysis
solutions (solution 5) were taken as an average from published
values for Gambrosol, StaySafe, and Dianeal. All solutions are
prepared using a commercially available 2.5% glucose
concentration peritoneal dialysis solution. Total GDP content as
measured by the summation of the individual glucose
degradation products measured.
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To date, the majority of evidence surrounding the
peritoneal toxicity of GDPs has focused on the effects
of GDPs on mesothelial cell injury.24 Only a few of these
low-molecular-weight aldehydes have been identified, with
several more GDPs visible by high-performance liquid
chromatography.7 Initial reports suggested that the acute
cellular toxicity due to GDPs was only achievable at high
concentrations, exceeding those found in PD fluids.25–27
However, the discovery of the GDP, 3,4-dideoxyglucosone-3-
ene (3,4-DGE), confirmed that concentrations of 3,4-DGE
found in conventional PD fluid could induce acute cellular
toxicity using an in vitro fibroblast culture model.28 Given the
nature of the cell lines used and the short duration of
incubation in previous studies (o72 h), specific conclusions
regarding in vivo long-term peritoneal effects remained
limited.
Using a culture of omental-derived HPMCs, Witowski
et al.24 demonstrated that exposure to six GDPs in
concentrations typically found in conventional PD solution
was not associated with short-term toxicity. However, after 6
weeks of exposure, the viability and function of the HPMCs
was severely comprised. It would appear that not all GDPs
have an equivalent capability for mesothelial cell toxicity.29
3,4-DGE has been shown to be among the most inhibitory
for mesothelial cell proliferation, and is also the only GDP
that has been demonstrated to enhance apoptosis of both
peripheral leukocytes as well as renal tubular epithelial
cells.29–31 In addition, 3,4-DGE and formaldehyde are among
the most potent GDPs responsible for impairment in
mesothelial cell repair in response to injury.32
GDP-induced mesothelial cell injury and apoptosis also
lead to intracellular hydrogen peroxide production and
free radical formation, which may be important inciting
events for peritoneal membrane inflammation and in-
jury.33,34 Moreover, GDPs have been shown to directly
induce production of the profibrotic cytokine transforming
growth factor-b and to stimulate vascular endothelial growth
factor (VEGF) synthesis in HPMCs.35–39 These two signaling
molecules are thought to have key roles in the progressive
peritoneal membrane fibrosis and vascular proliferation seen
in long-term PD patients.40 In a rat model, exposure to GDPs
has also been shown to stimulate excessive proliferation of
mesenchymal-like cells.41 These cells may be derived through
epithelial–mesenchymal transition (EMT), whereby perito-
neal mesothelial cells undergo transition to a fibroblast-like
phenotype and is thought to be a key mediator of peritoneal
fibrosis.42 Whether or not proliferation of mesenchymal cells
is directly stimulated by exposure to GDPs or indirectly by
GDP-induced upregulation of transforming growth factor-b
(a known stimulus for EMT) is unclear.42 Dialysate effluent
obtained from patients at 12 months after the initiation of
PD using low-GDP solutions contained fewer fibroblast-
dominant cells compared with the effluent obtained from
patients using conventional PD solutions, suggesting GDP-
induced EMT in vivo.43 Taken together, in vitro and animal
data suggest that peritoneal mesothelial cell integrity may be
adversely affected by the presence of GDPs in conventional
PD solution. The alterations in mesothelial cell viability may
initiate a cascade of events, leading to progressive peritoneal
membrane injury.
Advanced glycosylation end products
Under conditions of elevated glucose, advanced glycosylation
end products (AGE) are formed from the non-enzymatic
glycosylation of proteins.44 AGEs have the potential to
increase vascular permeability by disruption of the vascular
basement membrane due to protein cross-linking to base-
ment membrane components45 or by the activation of the
receptor for AGEs (RAGE) on endothelial cells.46
In vitro kinetic studies suggest that the formation of
AGEs on exposure to conventional PD solutions appears to
be largely mediated by the presence of GDPs.47 GDPs appear
to have greater reactivity than glucose in the formation of
AGEs and incubation with NpHLGDP PD solutions results in
lower systemic AGE levels compared with conventional PD
solutions incubated at similar concentrations of glucose.48,49
Moreover, in peritoneal effluent, AGEs have been detected at
levels greater than plasma, and appreciable staining for AGEs
has been demonstrated in the peritoneal membrane as early
as within the first 3 months of PD therapy.50,51
Rat models suggest that accelerated AGE formation may
have a causative role in PD solution-induced peritoneal
membrane injury.52 In these models, increased peritoneal
deposition of GDPs and AGEs and upregulation of the RAGE
are seen with exposure to conventional PD solutions
compared with NpHLGDP solutions.
52 Structurally, these
changes are accompanied by increases in submesothelial
fibrosis, VEGF production, and microvascular proliferation,
while functional changes include lower peritoneal UF.52
RAGE has also been detected on the surface of HPMCs.53
Stimulation of RAGE by AGEs results in VEGF release by
HPMCs, which leads to capillary tube formation of human
umbilical vein endothelial cells in a co-culture model.54 This
may be an important mechanism underlying the angiogenesis
of the peritoneal capillary network seen in long-term PD.54
Moreover, AGEs binding to RAGE on HPMCs also stimulate
activation and upregulation of vascular cell adhesion
molecule-1 on the mesothelial cell surface.55 Vascular cell
adhesion molecule-1 has an integral role in facilitating
leukocyte adhesion, which may activate an inflammatory
pathway and lead to peritoneal injury.56 Human peritoneal
biopsies suggest that AGE accumulation in the peritoneal
membrane occurs predominantly in the vessel wall. AGE
deposition correlates with increased time on therapy and
increased peritoneal permeability.57–59
Dialysate pH and lactate
Topley et al.60 investigated the effects of a lactate-buffered
(pH 5.5) PD solution compared with a bicarbonate-buffered
NpHLGDP PD solution on mesothelial cell toxicity using
HPMCs. Toxicity was seen exclusively in HPMCs incubated
with a lactat-buffered (pH 5.2) PD solution, but not when
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incubated using a bicarbonate-buffered (pH 7.4) PD
solution. However, it is possible that the difference in GDP
content between the two solutions was likely largely
responsible for the overall difference in mesothelial cell
function between the two groups.
In addition to pH, the choice of buffer, lactate versus
bicarbonate, appears to have an effect on HPMC metabolism,
irrespective of the osmotic agent used. Plum et al.61
compared HPMCs incubated at equivalent pH (7.4), but
with varying buffers (lactate versus bicarbonate) and osmotic
agents (glucose, amino acid, or glucose polymer solutions).
Independent of the osmotic agent, there was no difference in
the cell viability of HPMCs (using cytofluorometry to
measure apoptotic and necrotic cells) between lactate
versus bicarbonate-cultured HPMCs. However, ‘superior’
parameters of cell metabolism (improved interleukin-6 (IL-6)
release and ATP production) were demonstrated in the
bicarbonate, but not the lactate-incubated HPMCs. The
effect appeared to be independent of the osmotic agents used
in the culture medium.
More recently, Ogata et al.62 have demonstrated that
reduced HPMC metabolism (as measured by mitochondrial
activity) in lactate-incubated HPMCs, compared with
bicarbonate-incubated HPMCs, is accompanied by higher
levels of basic fibroblast growth factor in the supernatant
of HPMCs. Moreover, the higher levels of basic fibroblast
growth factor in the lactate-buffered supernatant led to a
greater degree of activation of human umbilical vein
endothelial cells and human peritoneal fibroblasts. These
findings suggest that the use of lactate may lead to reductions
in mesothelial cell metabolism and viability, while increasing
basic fibroblast growth factor production and local activation
of endothelial cells and fibroblasts. The use of bicarbonate
may abrogate these effects, translating into in vivo effects of
reduction in neovascularization and fibrosis of the peritoneal
membrane.
In addition to mesothelial cell toxicity, reduced dialysate
pH and use of lactate in conventional PD solutions may lead
to impaired peritoneal leukocyte function, compromising
local peritoneal host defenses. The phagocytic index for
bacteria was reduced when phagocytes were exposed to an
intraperitoneal pH of 5 compared with 7 (ref. 63). During the
lowest intraperitoneal pH at the initial phase of the PD
exchange, peritoneal macrophage function appears to be
transiently depressed, recovering over time as intraperitoneal
pH increases. Intracellular acidification and influx of lactate
from conventional PD solutions is likely responsible for the
inhibitory effect on peritoneal macrophages.64 Evaluation
of a bicarbonate/lactate-based PD solution, compared with
lactate-based solution, demonstrated that exposure to the
bicarbonate/lactate-based neutral pH fluid led to improve-
ment in peritoneal macrophage function, as measured by
increased tumor necrosis factor-a production.65,66 Similarly,
these findings were recapitulated using a lactate-based,
but low-GDP neutral pH solution that demonstrated
improved peritoneal leukocyte survival and respiratory
burst responses.67 However, given that GDPs have been
shown to promote peripheral leukocyte apoptosis,31 a lower
GDP content may have been partially responsible for
the improvement in peritoneal macrophage function in the
bicarbonate solution. Therefore, it is likely that the
improvements in peritoneal leukocyte function are due to
the combined effects of the buffer used, the effects of
increased intraperitoneal pH, and the effects of the lower
GDP content in the neutral pH solution. Moreover, whether
or not the in vitro cytotoxicity of dialysate pH at levels
present in conventional PD solutions similarly leads to in vivo
cytotoxicity is not known. It is possible that the in vivo
cytotoxicity of dialysate pH may be attenuated, given that
dialysate pH is depressed only for the first 10–30min of an
exchange, reaching a pH level that is similar to serum levels
after that time.
BIOMARKERS OF ‘BIOCOMPATIBILITY’
Although in vitro and animal data suggest that the
constituents of current conventional PD solutions contribute
to significant local peritoneal toxicity, confirmatory human
data is lacking, owing to the challenges in obtaining serial
Table 2 | Dialysate effluent markers in the evaluation of the biocompatibility of low-GDP neutral pH peritoneal dialysis
solutions
Dialysate effluent markers (relative to conventional PD solutions)
Study Study type
F/U
(months)
Solution
type N CA-125 VEGF IL-6 TGF-b TNF-a HA PICP
Kim et al.75 RCT 12 Balance 69 m — 2 — — — —
Choi et al.78 RCT 12 Balance 104 m — — — — — —
Rippe et al.77 RCT 24 Gambrosol Trio 80 m — — — — k m
Haag-Weber et al.76 RCT 20 Gambrosol Trio 69 m — — — — — —
Cooker et al.8 RCT 6 Physioneal 92 — 2a k — 2 — —
Szeto et al.82 RCT 12 Balance 50 m — — 2 — k —
Fusshoeller et al.80 Randomized crossover 5 Physioneal 12 m — k — — — —
Haas et al.79 Randomized crossover 3 Balance 40 m 2 — 2 — — —
Williams et al.81 Randomized crossover 6 Balance 71 m 2 — — 2 k m
Zeier et al.48 Randomized crossover 4 Gambrosol Trio 21 m — — — — — —
Abbreviations: CA-125, cancer antigen 125; F/U, follow up; GDP, glucose degradation product; HA, hyaluronic acid; IL-6, interleukin 6; PD, peritoneal dialysis; PICP, procollagen
peptide; RCT, randomized controlled trial; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
aSignificant difference at 3 months, but not at the end of follow-up.
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peritoneal membrane biopsies in patients while undergoing
PD therapy. Therefore, the majority of in vivo evidence
largely stems from the measurement of dialysate effluent
markers (Table 2). The utility of surrogate markers such as
dialysate cancer antigen-125 (CA-125), VEGF, and IL-6 for
the health and viability, and the inflammatory status of the
resident cells of the peritoneum is reviewed below.
Cancer antigen-125
CA-125 is a glycoprotein constitutively produced by
mesothelial cells, and is, therefore, a putative marker of
mesothelial cell mass and function.68–70 Declining dialysate
effluent CA-125 levels are seen with time on PD.71–74 These
findings support the histological findings of progressive loss
of mesothelial cell mass that have been observed with time on
PD.1 Across multiple studies, it has been established that
dialysate CA-125 levels are higher with the use of NpHLGDP
solutions compared with conventional PD solutions48,75–82
(Table 2). Interestingly, many of these studies, including a
recent study by Kim et al.75 and the Euro-Balance trial, have
shown that during the short period of observation, levels of
CA-125 in patients treated with NpHLGDP solutions rise over
time, whereas levels of CA-125 remain stable in patients
treated with conventional PD solutions.81 In the Euro-
Balance trial, after exposure to NpHLGDP PD solution for
only 12 weeks, levels of CA-125 increased three- to four-
fold.81 In both studies, however, it is not clear whether the
increase in CA-125 reflects increased mesothelial cell mass or
greater synthesis per remaining mesothelial cell. In a
prospective observational study of 110 incident patients
followed up for at least 1 year, there were no longitudinal
changes in dialysate CA-125 levels over time compared with
baseline. Moreover, dialysate effluent CA-125 levels were not
different between 55 patients treated with conventional PD
solutions and 55 patients treated with NpHLGDP PD
solutions.83
In the absence of studies examining the relationship
between effluent CA-125 levels and peritoneal membrane
morphology and function, alternative explanations exist. CA-
125 levels can increase in the face of inflammatory stimuli
such as peritonitis, in which the elevated dialysate effluent
CA-125 levels result, in part, from CA-125 release from
necrotic mesothelial cells.84 After recovery, effluent CA-125
levels appear to be similar to controls.84 In the study by Kim
et al.,75 one cannot exclude the possibility that elevated CA-
125 levels in the group treated with NpHLGDP solutions may
have been, in part, related to low-grade intraperitoneal
inflammation. The resultant increase in effluent CA-125
levels in the group of 48 incident patients treated with a
NpHLGDP PD solution was accompanied by a statistically
significant decrease in serum albumin, an increase in small-
solute transport, and a trend to increased serum C-reactive
protein relative to the 43 incident PD patients treated with
conventional PD solutions at 13 months. Moreover, in a
study by Oh et al.,85 effluent CA-125 levels were strongly
associated with the dialysate appearance of albumin, which
has been independently associated with systemic and
peritoneal membrane inflammation. Given that few long-
term, prospective, multicenter clinical studies have validated
the prognostic significance of effluent CA-125 levels on
clinical outcomes in PD patients, the utility of dialysate
CA-125 as a surrogate marker of peritoneal membrane health
and integrity may be limited.
Vascular endothelial growth factor
VEGF is produced by a wide range of human cell lines and
stimulates nitric oxide synthase activity, vascular perme-
ability, and angiogenesis.86,87 The capacity for local produc-
tion of VEGF in the human peritoneum stems from
documentation of VEGF synthesis in both HPMC culture
and in animal models.40,88,89 Moreover, in vivo and in vitro
findings suggest that mesothelial cells that have undergone
EMT have the capacity to synthesize VEGF.90 In humans,
production of VEGF in the peritoneal endothelium increases
with time on PD, and is accompanied by increase in vascular
density.91 Functionally, in humans, higher dialysate effluent
VEGF levels have been associated with increased peritoneal
small-solute and macromolecular permeability, likely a
reflection of an increase in the peritoneal vascular surface
area.92,93 A causal basis for this association stems largely from
animal data, in which local administration of VEGF appears
to induce peritoneal microvascular changes that are partially
reversible on treatment with anti-VEGF monoclonal anti-
bodies.40
VEGF production by HPMCs appears to be stimulated by
proinflammatory cytokines and by AGEs such as glycated
albumin, and not by glucose itself.88 In animal models,
effluent VEGF levels, peritoneal VEGF staining, and angio-
genesis appear to be reduced with intraperitoneal adminis-
tration of NpHLGDP solutions, compared with those treated
with conventional PD solutions.52 In humans, the impact of
NpHLGDP solutions on effluent levels has been examined in
several studies81,94,95 (Table 2). The majority of these studies
have not demonstrated appreciable differences in effluent
VEGF levels in those treated with either solution. As is the
problem with many dialysate effluent biomarkers, it is
possible that effluent VEGF levels may not be entirely
reflective of local peritoneal production, given that transperi-
toneal transport of VEGF from the systemic circulation to the
dialysate has been described.96 Moreover, dialysate effluent
VEGF levels are a reflection of total VEGF production by all
resident cells of the peritoneum. It is possible that NpHLGDP
solutions affect VEGF production differently across various
cell types (that is, mesothelial cells, fibroblasts, and
endothelial cells).
Interleukin-6
Mesothelial cells are the major source of intraperitoneal IL-6
synthesis.97 Evidence for local IL-6 production stems from
effluent levels, which are several fold higher than serum
levels.92 HPMCs secrete IL-6 in response to spent peritoneal
dialysate, tumor necrosis factor-a, and IL-1b.97 Dialysate
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effluent levels of IL-6 are associated with baseline peritoneal
transport status and downstream inflammatory factors such
as membrane chemoattractant protein-1, angiogenic factors
such VEGF, as well as adhesion molecules (that is, vascular
cell adhesion molecule-I, intercellular adhesion molecule-I),
suggesting that IL-6 may have a role in the initial induction
of peritoneal membrane inflammation.85 In the absence of
IL-6 receptors on mesothelial cells, activation of HPMC is
largely mediated by trans-signaling with peritoneal leuko-
cyte-mediated release of the soluble IL-6 receptor and
activation of the gp130 receptor on HPMCs by the soluble
IL-6/IL-6 complex.98
However, IL-6 also has anti-inflammatory effects, induc-
ing downregulation of inflammatory cytokines by activation
of IL-1 and tumor necrosis factor receptor antagonists.
Further confusing the role of IL-6 is the reported positive
association between dialysate effluent IL-6 levels and
dialysate effluent CA-125 levels, a putative marker of
mesothelial health and integrity.85 Although some studies
suggest that effluent IL-6 levels are reduced with treatment
with NpHLGDP solutions, this has not been confirmed by
other studies75,80 (Table 2). Until the role of IL-6 in
progressive peritoneal membrane injury as well as its
predictive value in assessing clinically meaningful end points
has been fully elucidated, its use as a biomarker of
biocompatibility will remain limited.
SYSTEMIC EFFECTS OF GDPS AND AGES
In diabetes, the vasculotoxicity of AGEs has been well
established and has been linked with the development of both
microvascular complications and accelerated atherosclero-
sis.99 Moreover, diabetic patients with ESRD have almost
twofold AGE deposition in systemic arterial walls compared
with diabetic patients without renal disease.100 Importantly,
and not often appreciated, plasma levels of AGE in HD
patients appear to be similar, if not higher, compared with
those seen in PD patients.101 Taken together, this would
suggest that uremia itself is independently associated with
elevated systemic AGE levels, irrespective of dialysis modality.
Whether or not the use of a NpHLGDP solution compared
with the use of conventional glucose-based lactate-buffered
solution can result in less systemic AGE formation was tested
in the Euro-Balance study.81 Serum AGE levels of carboxy-
methyllysine and imidazolone were measured in a subset of
study patients. In patients treated with the low-GDP
solution, local effluent levels of carboxymethyllysine and
imidazolone were unchanged, compared with treatment with
the conventional PD solution, but systemic serum levels of
both GDPs fell significantly compared with baseline values
over a 12-week period. It should be noted that absolute levels
of serum imidazolone remained relatively unchanged be-
tween the two groups.
These results suggest that exposure to a NpHLGDP PD
solution may lead to decreased systemic levels of some, but
not all, AGEs. The clinical significance of these findings needs
to be interpreted in the context of the Euro-Balance study
design. Only two known AGEs were measured. There was a
relatively short duration of observation (24 weeks), with the
measurement of AGEs in only a subset of patients. In this
study and in others, no correlation could be demonstrated
among circulating plasma AGE levels, tissue AGE deposition,
and clinical outcomes. Moreover, in HD patients, the
demonstration that elevated plasma levels of carboxymethyl-
lysine are associated with a survival advantage calls into
question the prognostic significance of elevated levels of
serum AGE in PD patients.102
CLINICAL OUTCOMES USING LOW-GDP, NEUTRAL pH PD
SOLUTIONS
Peritonitis
Local peritoneal immunity has an important role in the
prevention and resolution of PD peritonitis. When exposed
to conventional dialysate, however, there is abnormal
leukocyte recruitment in response to inflammatory stimuli103
and impaired phagocytic function.104
Given that impaired peritoneal immunity is thought to be,
in part, due to the bioincompatibility of the conventional
dialysis solutions used, several studies have sought to
determine whether the NpHLGDP PD solutions might be
associated with improved peritoneal immune function. In a
small, randomized crossover study, the use of NpHLGDP
dialysate for 6 months was associated with enhanced
phagocytic activity of peritoneal macrophages.80 Another
small, randomized crossover study showed an increase in the
number of peritoneal effluent macrophages after 3 months of
exposure to NpHLGDP solutions.
105
Several observational studies have sought to assess
whether these differences in markers of peritoneal immunity
translate into reduced peritonitis risk, with conflicting
results. The largest of these studies was a retrospective cohort
study of 1909 incident Korean patients on CAPD between
2002 and 2005.106,107 Although patient survival was greater
among the patients treated with the NpHLGDP solutions (see
later), there was no difference in peritonitis-free survival or
peritonitis rate.106,107 In contrast, in a study by Ahmad
et al.108 from 2002 to 2004, the peritonitis rate was
significantly lower among patients using NpHLGDP solutions
(1 in 52.5 patient-months versus 1 in 26.9 patient-months).
Another observational study comparing peritonitis rates in
100 incident CAPD patients treated with either conventional
or NpHLGDP solutions similarly found a lower peritonitis
rate among those using the latter.109 Results are supported by
a third study in which 67 patients treated with conventional
PD solutions from 1990 to 1999 were compared with 53
patients treated with a NpHLGDP solution from 2000 to 2005,
with the latter group having a lower peritonitis rate.110
The basis for the conflicting results of these observational
studies may relate to residual confounding between the
conventional and NpHLGDP PD solution groups. As patients
in these studies were not randomized to one or other
treatment, it is possible that patients receiving NpHLGDP PD
solutions differed in several respects, including their under-
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lying comorbidities or other aspects of their PD therapy that
could have influenced peritonitis risk. This latter issue is
particularly relevant in studies comparing patients across
eras, as those receiving NpHLGDP solutions are more
contemporary cohorts that are known to have lower
peritonitis rates.111 There are only two randomized trials to
date of conventional versus biocompatible PD fluids that
included data on infectious outcomes (Table 3).76,112 In the
first of these studies, Fan et al.112 randomized 93 incident PD
patients to conventional or NpHLGDP PD solutions for 1 year,
with RKF as the primary end point and peritonitis as a
secondary end point. There were no significant difference in
the peritonitis rates. Similarly, Haag-Weber et al.76 rando-
mized 80 patients to standard or NpHLGDP dialysate for
18 months. Although peritonitis was not their primary end
point, there was no difference in peritonitis risk between the
groups. Although neither of these studies was powered for
the outcome of peritonitis, there was no suggestion of benefit
of the newer solutions, with respect to peritonitis risk.
Further randomized controlled studies powered to study the
occurrence of peritonitis with different PD solutions are
required to clarify whether improvements in putative
markers of peritoneal immunity translate into reduced
peritonitis risk.
Peritoneal membrane function
UF failure remains one of the major sources of late technique
failure for patients on PD.113 Longitudinal changes in
peritoneal membrane function include increases in peritoneal
membrane small-solute permeability and reduction in perito-
neal UF capacity.114 If the use of NpHLGDP PD solutions could
slow or reverse these changes, then it is possible that their use
could translate into clinically meaningful outcomes.
Several studies using NpHLGDP PD solutions have suggested
no improvement in peritoneal UF or longitudinal differences in
peritoneal small-solute permeability36,50,69,86,93,104 (Table 3).
In fact, several recent studies have demonstrated that use of
NpHLGDP solutions is associated with reduction in peritoneal
UF, which may be partially explained by an accompanying
increase in small-solute permeability.
Interpretation of these studies is limited for several
reasons. In all the studies, peritoneal membrane function
was not studied as a primary end point. Several studies were
limited by non-randomized treatment allocation. In the
study by Kim et al.,75 baseline small-solute transport
characteristics were not provided, and so follow-up measures
may reflect case mix differences between the groups at
baseline. Moreover, selection bias of patients with a tendency
to relatively better preservation of peritoneal membrane
function may have occurred in several studies. This may be
the result of recruitment of prevalent patients and the effects
of informative censoring, leading to absence of longitudinal
values on peritoneal membrane function in patients who died
or were transferred to HD. The relatively short follow-up
of these studies (majority o1 year) makes it difficult to
extrapolate the impact of low-GDP solutions on peritoneal
membrane function beyond 1–2 years of PD therapy. Lastly,
the variability of PD solutions across studies in terms of the
buffer, GDP content, and co-intervention in some study
protocols with the use of non-glucose-based PD solutions,
further limit conclusions regarding their impact.
Residual kidney function
Across observational studies, the preservation of RKF is a
consistent and potent predictor of patient survival in both
PD and HD patients.115,116 Therefore, strategies aimed at
RKF preservation represent an important therapeutic target
in the management of PD patients. The ability of GDPs to
promote renal tubular apoptosis in cell culture, coupled with
the established role of AGEs in the induction of glome-
ruloscelerosis and progression of diabetic nephropathy, has
led to the hypothesis that the use of a NpHLGDP solution may
be associated with better preservation of RKF compared with
traditional PD solutions.30,117 The Euro-Balance and several
other studies have purported to demonstrate better pre-
servation of RKF (Table 3).75,76,78,81,82,118 Moreover, results
from Montenegro et al.,118 using a pure bicarbonate PD
solution, supported these findings. In both studies, and in the
recent study by Kim et al.,75 the resultant improvement in
RKF was accompanied by a statistically significant decrease in
Table 3 | Clinical outcomes using low-GDP neutral pH PD solutions: peritoneal membrane
Study N Follow-up Population Design Solution RKFa
Daily
UF
Small-
solute
transport Peritonitis
Williams et al.81 86 24 Weeks
(12/12)
Prevalent Multicenter/crossover
RCT
Balance m k m 2
Fan et al.112 93 1 Year Incident APD/CAPD Single-center RCT Physioneal/balance 2 2 2 2
Choi et al.78 104 1 Year Prevalent CAPD Single-center RCT Balance 2 m 2 NR
Montenegro et al.118 36 1 Year Incident CAPD Prospective observational Bicavera m k 2 NR
Szeto et al.82 50 1 Year Incident CAPD Single-center RCT Balance 2 2 2 2
Kim et al.75 91 1 Year Incident CAPD Multicenter RCT Balance m k m 2
Haag-Weber et al.76 69 20 Months Incident/prevalent CAPDb Multicenter RCT Gambrosol Trio m —c —c 2
Abbreviations: APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; GDP, glucose degradation products; NR, not reported; PD, peritoneal
dialysis; RCT, randomized controlled trial; RKF, residual kidney function; UF, ultrafiltration.
aResidual kidney function, as measured by the mean of 24-h collection for urea and creatinine clearances standardized for body surface area.
bFour patients were treated with automated peritoneal dialysis.
cDaily ultrafiltration not corrected for overfill and data not provided for peritoneal small solute transport.
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peritoneal UF. This may have been, in part, the driving source
for the higher RKF seen, reflecting differences in volume
status during treatment between traditional and biocompa-
tible PD solutions. Both studies were crossover trials with a
short duration of follow-up, limiting the interpretation of the
findings. A recent, well-powered, randomized controlled trial
by Fan et al.112 refuted these findings. With RKF as the
primary end point, this study did not demonstrate a benefit
with the use of biocompatible (bicarbonate/lactate) solutions
on RKF preservation in a group of 93 PD patients. Similar
findings were also noted by Szeto et al.82 using the same
solutions as in the Euro-Balance trial. A recent multicenter
randomized controlled trial comparing a lactate-based low-
GDP PD solution with a conventional PD solution revealed a
slower rate of RKF decline in the group receiving the low-
GDP solution.76 However, unlike most studies, RKF decline
was modeled exponentially rather than linearly as in most
studies to date, and no information was provided on
peritoneal membrane function throughout the study.
The basis for the conflicting study results may, in part,
reflect the different solutions used, each with its own profile
of potentially glomerulotoxic and vasculotoxic GDPs. In
addition, the studies included a heterogeneous mix of both
incident and prevalent PD patients. Finally, the contribution
of reduced UF and relative volume overload with the newer
solutions confuses the issue even more. In the absence of
further prospective studies, definitive conclusions regarding
the impact of biocompatible solutions on RKF preservation
cannot be drawn.
Survival
Most clinical studies of biocompatible solutions have focused
on outcomes such as peritonitis, RKF, and peritoneal
membrane function. Only two studies to date have sought
to identify whether the use of biocompatible solutions is
associated with improved patient survival. The first of these
two studies by Lee et al.106 was a prospective, longitudinal
observational cohort study of 1909 Korean PD patients
followed up between 2002 and 2005. Although no difference
in technique survival was observed between groups, there was
higher patient survival among those who received the
biocompatible solutions relative to conventional solutions
in the multivariable model. This was followed by an
extension of the first study to include an observational
cohort study of Korean PD patients followed up between
2003 and 2006.119 Again, there were significant baseline
differences in patient characteristics between those using
biocompatible solutions versus conventional solutions. After
propensity matching and multivariable adjustment, patient
survival was better among patients using the biocompatible
solutions, with a hazard ratio of 0.7. Of concern, outcomes
were assessed in the first study appropriately by an
‘intention-to-treat’ model, whereas in the extended study
this was not done, so that the healthier patients switched
from conventional to new solutions were simply removed
from the analysis.
Although the results of these studies are interesting, it is
difficult to avoid the issue of residual confounding using
these observational data sources. For example, although
some important covariates were adjusted for in both studies,
others such as more detailed patient comorbidities, RKF,
inflammatory status, and era of solution use were not.
Furthermore, both studies included only Korean PD patients
and the second study included patients with very low
cardiovascular morbidity, such that the observed findings
may not be generalizable. As with all of the aforementioned
clinical outcomes, the only way to definitively answer
whether biocompatible solutions impart a survival advan-
tage would be to do a large, multicenter randomized
controlled trial.
CONCLUSION
There is a growing literature to support the relative
bioincompatibility of conventional dialysate, as well as the
link between these unphysiological conditions and alterations
in peritoneal membrane morphology and function. This has
led to the use of NpHLGDP solutions in an attempt to better
preserve the peritoneal membrane among patients on long-
term PD. Although there is biological plausibility and in vitro
and animal data to suggest potential benefit of these newer
solutions, consistent clinical outcome data are lacking.
Surrogate markers of biocompatibility should be viewed
with caution, and careful validation against important
clinical end points are needed before their adoption as study
end points.
Studies to date have largely been observational in nature,
and have examined surrogate clinical outcomes including
RKF and peritoneal membrane function. Most published
randomized controlled trials have been relatively small,
single-center studies and, therefore, underpowered to detect
clinically meaningful differences. Future multicenter studies
are required that recruit patients from multiple continents
and focus on clinically relevant solid end points, including
peritonitis, technique, and patient survival. Furthermore,
significant differences in both the profile and the absolute
concentration of GDPs in available NpHLGDP solutions
exist, and this is often not accounted for when comparing
studies. These issues have led to conflicting results and
much confusion in trying to interpret the literature. Given
the incremental cost associated with the long-term use of
NpHLGDP solutions, further study is warranted before
biocompatible solutions can be considered the standard of
care in the management of PD patients.
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